Full-Time

Senior Consultant

Sfdc

Confirmed live in the last 24 hours

Deadline 5/30/25
AstraZeneca

AstraZeneca

10,001+ employees

Develops and commercializes prescription medicines

No salary listed

Senior

Chennai, Tamil Nadu, India

Minimum of three days per week in the office.

Category
IT Consulting
Consulting
Required Skills
Salesforce
Requirements
  • Overall 6+ years of development experience with a minimum of 4+ years of Salesforce Development experience
  • Experience in Salesforce Service Cloud implementations and communities
  • Salesforce Development/Customizations, Lightning Components experience
  • Design and implement solutions leveraging Salesforce out-of-box features
  • Excellent problem-solving and analytical skills
  • Design and improve internal development methodologies
  • Propose technology solutions to enable the business to meet/exceed those goals
  • Analyze business requirements and create technical design documents that are in accordance with the company's architecture standards
  • Demonstrates strong understanding of the business needs driving the projects
  • Familiarity with modern development practices and the software development life cycle
  • Excellent communication and organizational skills
  • Ability to manage multiple priorities, meet deadlines, and produce quality results under pressure
  • Master’s / Bachelor’s degree or equivalent
Responsibilities
  • Design and implement solutions leveraging Salesforce out-of-box features
  • Analyze business requirements and create technical design documents that are in accordance with the company's architecture standards
  • Propose technology solutions to enable the business to meet/exceed those goals
  • Design and improve internal development methodologies

AstraZeneca focuses on discovering, developing, and selling prescription medicines, primarily in three areas: Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Their products are developed through extensive research and development, which includes rigorous clinical trials and regulatory approvals before reaching the market. AstraZeneca differentiates itself from competitors by investing heavily in scientific research and fostering collaborations through initiatives like their Open Innovation program, which shares resources with the scientific community to speed up drug discovery. The company's goal is to advance healthcare by creating effective treatments for serious diseases and expanding their product offerings through strategic partnerships.

Company Size

10,001+

Company Stage

IPO

Headquarters

Cambridge, United Kingdom

Founded

1913

Simplify Jobs

Simplify's Take

What believers are saying

  • AstraZeneca's new facilities enhance manufacturing capabilities and job creation in key regions.
  • AI-powered tools improve lung cancer detection, showcasing AstraZeneca's innovation in diagnostics.
  • Enhertu's success in breast cancer trials strengthens AstraZeneca's oncology portfolio.

What critics are saying

  • Increased competition in oncology may impact AstraZeneca's market share.
  • Regulatory delays could affect the timely launch of new AstraZeneca products.
  • Emerging biosimilars may erode sales of AstraZeneca's established biologic drugs.

What makes AstraZeneca unique

  • AstraZeneca's A.Catalyst Network fosters global collaboration and innovation in healthcare.
  • The company invests heavily in R&D for new drug discovery and development.
  • AstraZeneca's Open Innovation program accelerates drug discovery by sharing resources with scientists.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Paid Holidays

Flexible Work Hours

Company News

The Pharma Letter
May 12th, 2025
AstraZeneca breaks ground on $475 million drug plant in Wuxi

AstraZeneca breaks ground on $475 million drug plant in Wuxi.

MocoShow
May 9th, 2025
AstraZeneca Opens $300 Million CAR-T Manufacturing Facility in Rockville, Creating Over 150 Jobs

AstraZeneca opens $300 million CAR-T manufacturing facility in Rockville, creating over 150 jobs.

Montgomery County Government
May 9th, 2025
AstraZeneca Opens $300 Million Cell Therapy Manufacturing Facility in Montgomery County

AstraZeneca opens $300 million cell therapy manufacturing Facility in Montgomery County.

Cision
May 9th, 2025
Imfinzi Improved Dfs In Early Bladder Cancer

Imfinzi improved DFS in early bladder cancer

PharmiWeb
May 7th, 2025
Enhertu Followed By Thp Before Surgery Showed Statistically Significant And Clinically Meaningful Improvement In Pathologic Complete Response In Patients With High-Risk Her2-Positive Early-Stage Breast Cancer In Destiny-Breast11 Phase Iii Trial

AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety profile vs. standard of careFirst Phase III trial to demonstrate benefit of Enhertu in early breast cancer. Positive high-level results from the DESTINY-Breast11 Phase III trial showed Enhertu (trastuzumab deruxtecan) followed by paclitaxel, trastuzumab and pertuzumab (THP) demonstrated a statistically significant and clinically meaningful improvement in pathologic complete response (pCR) rate versus standard of care (dose-dense doxorubicin and cyclophosphamide followed by THP [ddAC-THP]) when used in the neoadjuvant setting (before surgery) in patients with high-risk, locally advanced HER2-positive early-stage breast cancer. Pathologic complete response is defined as no evidence of invasive cancer cells in the removed breast tissue and lymph nodes following treatment. The secondary endpoint of event-free survival (EFS) was not mature at the time of analysis; however, EFS data showed an early positive trend favouring Enhertu followed by THP compared to standard of care. The trial will continue to follow EFS